Literature DB >> 9143872

Pharmacokinetics of an antifibrotic agent, pirfenidone, in haemodialysis patients.

M Taniyama, S Ohbayashi, M Narita, R Nakazawa, S Hasegawa, N Azuma, S Teraoka, K Ota, S Yamauchi, S B Margolin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9143872     DOI： 10.1007/s002280050252

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  5 in total

Review 1.  Recognition and treatment of idiopathic pulmonary fibrosis.

Authors:  L P Nicod
Journal:  Drugs       Date:  1998-04       Impact factor: 9.546

Review 2.  Transforming growth factor-beta: a clinical target for the treatment of diabetic nephropathy.

Authors:  Tracy A McGowan; Yanqing Zhu; Kumar Sharma
Journal:  Curr Diab Rep       Date:  2004-12       Impact factor: 4.810

Review 3.  Pirfenidone: an anti-fibrotic therapy for progressive kidney disease.

Authors:  Monique E Cho; Jeffrey B Kopp
Journal:  Expert Opin Investig Drugs       Date:  2010-02       Impact factor: 6.206

4.  Pirfenidone is renoprotective in diabetic kidney disease.

Authors:  Satish P RamachandraRao; Yanqing Zhu; Timothy Ravasi; Tracy A McGowan; Irene Toh; Stephen R Dunn; Shinichi Okada; Michael A Shaw; Kumar Sharma
Journal:  J Am Soc Nephrol       Date:  2009-07-02       Impact factor: 10.121

5.  Pharmacokinetics of pirfenidone after topical administration in rabbit eye.

Authors:  Guoying Sun; Xianchai Lin; Hua Zhong; Yangfan Yang; Xuan Qiu; Chengtian Ye; Kaili Wu; Minbin Yu
Journal:  Mol Vis       Date:  2011-08-13       Impact factor: 2.367
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.